الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 115 |  |  |
| | | from | 115 | | |
Abstract
HCC is a significant and escalating worldwide health concern. It is the sixth most prevalent form of cancer globally. Additionally, it ranks as the fourth most prevalent cause of cancer-related mortality worldwide. The primary cause of HCC in Egypt is HCV infection.
The available options for HCC treatment include surgical, locoregional and systemic therapies. However, only few patients with early HCC stage are amenable to surgical options, and most patients are amenable to loco-regional therapies.
CK 19 is a hepatic progenitor cell marker which considered a special subtype of HCC characterized by clinical aggressiveness and resistance to locoregional treatment such as RFA and TACE and systemic therapy. CK19 immunohistochemistry in tissue is the main detection tool for CK19. Hence, while the growing attention towards CK19 as a prognostic biomarker, several obstacles need to be addressed, given that liver biopsy is not a standard procedure for HCC patients.
An aggressiveness score was established to assess the aggressiveness of HCC and to predict prognosis. It includes maximum tumor diameter, serum AFP, number of lesions and the presence of portal vein thrombosis